PureTech Health, Johnson & Johnson and Novartis are in line for exits after the cancer drug developer filed for its initial public offering.

Vor Biopharma, a US-based developer of treatments for haematological malignancies, has filed for a $150m initial public offering that would allow pharmaceutical firms Johnson & Johnson, Novartis and PureTech Health to exit. Founded in 2015, Vor is working on drug treatments for haematological malignancies, a type of cancer that affects the blood, bone marrow and…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.